NCI intramural program approach to rare tumors: Natural history study of rare solid tumors in children and adults: A longitudinal, comprehensive data and biospecimen collection protocol.
adult rare tumor
natural history
pediatric rare tumor
rare tumor
young adult rare tumor
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
21 Jun 2023
21 Jun 2023
Historique:
revised:
06
05
2023
received:
13
01
2023
accepted:
04
06
2023
medline:
22
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
aheadofprint
Résumé
Rare tumors across the world are lacking adequate knowledge, resources, and community. Through partnership with patients, advocacy organizations, researchers, and clinicians, we have developed a comprehensive, longitudinal, prospective, and retrospective natural history protocol to collect, analyze, and share data on patients with rare tumors. A strong collaborative effort is vital to ensure success of enrollment, patient engagement, data collection, and analysis to ultimately develop clinical trials to improve outcomes for patients with rare cancers.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30495Subventions
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIDA NIH HHS
ID : 75N95021D00012
Pays : United States
Informations de copyright
Published 2023. This article is a U.S. Government work and is in the public domain in the USA. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Bradford D, Reilly KM, Widemann BC, Sandler A, Kummar S. Developing therapies for rare tumors: opportunities, challenges and progress. Expert Opin Orphan Drugs. 2016;4(1):93-103.
Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL. The occurrence of rare cancers in U.S. adults, 1995-2004. Public Health Rep. 2010;125(1):28-43.
Cunningham RM, Walton MA, Carter PM. The major causes of death in children and adolescents in the United States. N Engl J Med. 2018;379(25):2468-2475.
Hippert F, Desing L, Diez S, et al. Rare tumors in children and adolescents - the STEP Working Group's evolution to a prospective registry. Klin Padiatr. 2022;234(3):146-153.
Ferrari A, Bisogno G, De Salvo GL, Indolfi P, Perilongo G, Cecchetto G. The challenge of very rare tumours in childhood: the Italian TREP project. Eur J Cancer. 2007;43(4):654-659.
Clay MR, Pinto EM, Cline C, et al. DNA methylation profiling reveals prognostically significant groups in pediatric adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. JCO Precis Oncol. 2019;3:PO1900163. doi:10.1200/po.19.00163
Malignant Germ Cell International Consortium. MAGIC; 2021. Accessed April 15, 2023. www.magicconsortium.com
International Ovarian and Testicular Stromal Tumor Registry. OTST Registry; 2012. Accessed April 15, 2023. www.otstregistry.org
The International Pleuropulmonary Blastoma/DICER1 Registry. PPB/DICER1Registry; 2023. Accessed April 15, 2023. www.ppbregistry.org
The European Cooperative Study Group for Pediatric Rare Tumors. EXPeRT; 2013. Accessed April 15, 2023. www.raretumors-children.eu
Rodriguez-Galindo C, Krailo MD, Krasin MJ, et al. Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy: results of the Children's Oncology Group ARAR0331 study. J Clin Oncol. 2019;37(35):3369-3376.
Rodriguez-Galindo C, Krailo MD, Pinto EM, et al. Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the Children's Oncology Group ARAR0332 protocol. J Clin Oncol. 2021;39(22):2463-2473.
Dunkel IJ, Piao J, Chantada GL, et al. Intensive multimodality therapy for extraocular retinoblastoma: a Children's Oncology Group trial (ARET0321). J Clin Oncol. 2022;40(33):3839-3847.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739.
Fair D, Potter SL, Venkatramani R. Challenges and solutions to the study of rare childhood tumors. Curr Opin Pediatr. 2020;32(1):7-12.
Schott AF, Welch JJ, Verschraegen CF, Kurzrock R. The National Clinical Trials Network: conducting successful clinical trials of new therapies for rare cancers. Semin Oncol. 2015;42(5):731-739.
Davis LE, Janeway KA, Weiss AR, et al. Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer. 2017;123(18):3434-3440.
Avutu V, Weiss AR, Reed DR, et al. Identified enrollment challenges of adolescent and young adult patients on the nonchemotherapy arm of Children's Oncology Group study ARST1321. J Adolesc Young Adult Oncol. 2022;11(3):328-332.
Mittal N, Langevin A-M, Kyono W, et al. Barriers to pediatric oncologist enrollment of adolescents and young adults on a cross-network national clinical trials network supportive care cancer clinical trial. J Adolesc Young Adult Oncol. 2022;11(1):117-121.
Okuma HS, Yonemori K, Narita SN, et al. MASTER KEY Project: powering clinical development for rare cancers through a platform trial. Clin Pharmacol Ther. 2020;108(3):596-605.
Brown AL, Sok P, Scheurer ME, et al. An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: a Children's Oncology Group report. Cancer. 2022;128(14):2760-2767.
Tai E, Buchanan N, Westervelt L, Elimam D, Lawvere S. Treatment setting, clinical trial enrollment, and subsequent outcomes among adolescents with cancer: a literature review. Pediatrics. 2014;133(3):S91-S97.
Thomas SM, Malvar J, Tran H, Shows J, Freyer DR. A prospective, observational cohort study comparing cancer clinical trial availability and enrollment between early adolescents/young adults and children. Cancer. 2018;124(5):983-990.
Rare diseases: natural history studies for drug development: draft guidance for industry. Guidance Document. Center for Biologics Evaluation and Research; April 15, 2020. Accessed November 16, 2020.
Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007;45(5):S3-S11.
Cella D, Gershon R, Lai J-S, Choi S. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual Life Res. 2007;16:133-141.
Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978;37(4):378-381.
Wolters PL, Martin S, Merker VL, et al. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology. 2013;81(21):S6-S14.
Martin S, Nelson Schmitt S, Wolters PL, et al. Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report. Pain Med. 2015;16(2):367-373.
Holmström L, Kemani MK, Kanstrup M, Wicksell RK. Evaluating the statistical properties of the Pain Interference Index in children and adolescents with chronic pain. J Dev Behav Pediatr. 2015;36(6):450-454.
Wiener L, Battles H, Zadeh S, Smith CJ, Helman LJ, Kim SuY. Gastrointestinal stromal tumor: psychosocial characteristics and considerations. Support Care Cancer. 2012;20(6):1343-1349.
Lyon ME, Wiener L. Special issue: psychosocial considerations for children and adolescents living with a rare disease. Children (Basel). 2022;9(7):1099.
Allen T, Reda S, Martin S, et al. The needs of adolescents and young adults with chronic illness: results of a quality improvement survey. Children (Basel). 2022;9(4):500.